- •Preface
- •Contents
- •Contributors
- •1.1 Introduction
- •1.2 Pathogenesis of AMD
- •1.2.1 Oxidative Damage
- •1.2.2 Lipofuscin Accumulation
- •1.2.4 Complement Mutations
- •1.2.5 Mitochondrial Damage
- •1.2.6 DICER 1
- •1.3 Treatment
- •1.3.1 Antioxidants
- •1.3.2 Visual Cycle Modulators
- •1.3.4 Neurotrophic Agents
- •1.3.5 Antiangiogenic Agents
- •1.3.5.1 Intracellular Angiogenic Factor Production
- •1.3.5.2 Extracellular Angiogenic Factors
- •1.3.6 Endothelial Cell Receptor Binding
- •1.3.7 Endothelial Cell Activation
- •1.3.8 Endothelial Cell Proliferation
- •1.3.9 Endothelial Cell Directional Migration
- •1.3.10 Extracellular Matrix Remodeling
- •1.3.11 Tube Formation
- •1.3.11.1 Loop Formation (Arteriovenous Differentiation)
- •1.3.11.2 Vascular Stabilization
- •1.4 Combination Therapy
- •1.5 Conclusions
- •References
- •2.1 Introduction
- •2.1.1 Complement Pathways
- •2.1.2 Oxidative Stress
- •2.3.1 The Mouse CNV Model
- •2.3.2 RPE Monolayers
- •2.3.3 Concept
- •2.5 Summary and Outlook
- •References
- •3.1 Introduction
- •3.2.1 Advanced Glycation End Products
- •3.2.2 Carboxyethylpyrrole
- •3.2.3 Oxidation Products of Lipofuscin
- •3.3 Summary and Conclusions
- •References
- •4.1 Introduction
- •4.2 Oxidative Stress and AMD
- •4.2.1 Basic Concepts on Oxidative Stress
- •4.2.2 Oxidative Stress in AMD
- •4.3 Malondialdehyde in AMD
- •4.3.1 Lipid Peroxidation and Malondialdehyde
- •4.3.2 Materials and Methods
- •4.3.2.1 RPE Cell Culture
- •4.3.2.2 Patients
- •4.3.2.3 MDA Assay
- •4.3.3 MDA Levels in Cultured RPE Cells and in Patients with AMD
- •4.4 Summary and Conclusions
- •References
- •5.1 Introduction
- •5.2 The Origin and Housing of RPE Lipofuscin
- •5.3 Bisretinoid Constituents of RPE Lipofuscin
- •5.3.1 A2E, Isomers and Precursors
- •5.3.4 Photooxidized Forms of Bisretinoid Pigments
- •5.4 Photoreactivity of RPE Lipofuscin
- •5.5 Photooxidation of RPE Bisretinoids
- •5.6 Bisretinoid Photodegradation
- •5.7 Potential for Cell and Tissue Damage
- •5.9 A Role for Antioxidants
- •5.10 Conclusions
- •References
- •6.1 Introduction
- •6.1.1 RPE Lipofuscin Accumulation with Age and Relation to AMD
- •6.1.2 Known Chromophores Found in RPE Lipofuscin and the Mechanism of Damage
- •6.1.3 Formation of Higher Molecular Weight Material
- •6.1.4 Current Studies and Possible Structures of Higher Molecular Weight Products
- •6.1.4.1 Lipofuscin Extracts
- •6.1.4.3 Esters and Aldehydes
- •6.2 Conclusions
- •References
- •7.2 DHA in Photoreceptor Cells
- •7.3 Neuroprotectin D1 Synthesis is an Early Response to Oxidative Stress in RPE Cells
- •7.5 Neurotrophins Trigger the Synthesis and Polarized Secretion of Neuroprotectin D1 from Human RPE Cells
- •7.6 Photoreceptor Outer Segment Phagocytosis Induces RPE Cell Survival Signaling with Associated Synthesis of NPD1 During Oxidative Stress
- •References
- •8.1 Introduction
- •8.2.1 Subcellular Localization
- •8.2.2 Expression Levels in the Retina
- •8.4.3 Regulation of RDH12 Expression and Activity During Chronic and Acute Stress
- •8.5 RDH12 and Leber Congenital Amaurosis
- •8.5.1 Inactivating Mutations of RDH12
- •8.5.2 Loss of Which RDH12 Function Induces LCA?
- •8.6 Summary and Conclusions
- •References
- •9.1 Introduction
- •9.2 GSH Metabolism: General Principles
- •9.2.2 Role of Mitochondrial GSH in Protection
- •9.2.3 GSH as a ROS Scavenger
- •9.2.4 GSH Distribution in the Retina and RPE in Health and Disease
- •9.5 Future Perspectives
- •References
- •10.1 Introduction
- •10.2 Mitochondria
- •10.2.1 Mitochondrial Biogenesis and Maintenance
- •10.2.2 Mitochondrial Removal and Degradation
- •10.3 Mitochondria and Reactive Oxygen Species
- •10.3.1 Reactive Oxygen and Nitrogen Species (ROS and RNS)
- •10.3.2 Mitochondria are a Major Source of Intracellular ROS
- •10.3.3 Other Sources of ROS in the Retina
- •10.4 The Mitochondrial Genome
- •10.4.1 Susceptibility of Mitochondrial DNA to Oxidative Stress
- •10.4.2 Mitochondrial DNA Damage
- •10.4.3 Mitochondrial DNA Repair Pathways
- •10.4.4 The Mitochondrial Base Excision Repair (mtBER) Pathway
- •10.4.6 Other Mitochondrial DNA Repair Pathways
- •10.4.6.2 Mismatch Repair (MMR)
- •10.4.6.3 Translesion Synthesis (TLS) and Damage Tolerance
- •10.4.6.4 Nucleotide Excision Repair (NER)
- •10.4.7 Intramitochondrial Localization of DNA Repair Proteins
- •10.4.8 mtDNA Damage Sensing and Signaling
- •10.4.9 Import of Nuclear Encoded DNA Repair Enzymes into the Mitochondria
- •10.5 Mitochondrial DNA Damage/Repair in the Retina and RPE
- •10.5.1 Mitochondrial DNA Damage/Repair in the RPE
- •10.5.2 DNA Repair and the Adaptive Response in the RPE
- •10.6 Pathologies Associated with Mitochondrial Dysfunction and Oxidative Stress in the Retina
- •10.6.2 Diabetic Retinopathy
- •10.6.3 Glaucoma
- •10.6.4 Uveitis
- •10.7 Pathologies Associated with Inherited Mitochondrial Disorders
- •10.8 Potential Therapeutic Options for Targeting Mitochondrial DNA Damage
- •10.8.1 Mitochondrial Biogenesis
- •10.8.2 Enhancing mtDNA Repair
- •10.8.3 Antioxidants
- •10.8.4 Autophagy
- •10.9 Conclusion
- •References
- •11.1 Introduction
- •11.2 ER Function in Normal Physiology
- •11.2.1 Major Roles of Rough ER (RER) and Smooth ER (SER)
- •11.2.2 ER and Oxidative Protein Folding
- •11.2.3 ER Resident Proteins
- •11.2.4 Potential Threat to ER Function in RPE
- •11.3 ER Response to Oxidative Stress in RPE
- •11.3.2 Initiation of UPR to Alleviate ER Burden
- •11.4 Chronic ER Stress and Oxidative Stress in the Vicious Cycle of Apoptosis Induction
- •11.5 Future Perspectives
- •References
- •12.1 Introduction
- •12.2 Iron Homeostasis
- •12.2.1 General Iron Homeostasis
- •12.2.2 Iron Import into the Retina
- •12.2.2.1 Transferrin Mediated Transport
- •12.2.2.3 Dexras
- •12.2.3 Iron Storage
- •12.2.3.1 Ferritin
- •12.2.3.2 Mitochondrial Ferritin
- •12.2.4 Iron Export
- •12.2.4.1 Ceruloplasmin
- •12.2.4.2 Hephaestin
- •12.2.4.3 Ferroportin and Hepcidin
- •12.3 Disruption of Iron Homeostasis and Oxidative Damage
- •12.4 Retinal Disorders Resulting from Abnormal Retinal Iron Metabolism
- •12.4.2 Aceruloplasminemia
- •12.4.3 Hemochromatosis
- •12.4.4 Friedreich’s Ataxia
- •12.4.6 Siderosis
- •12.4.7 Subretinal Hemorrhage
- •12.5 Potential Therapeutics
- •References
- •13.1 Vascular Endothelial Growth Factor and Its Functions in the Retina
- •13.1.1 VEGF Isoforms
- •13.1.2 VEGF Functions
- •13.1.3 Cells Secreting VEGF in the Retina
- •13.1.3.1 Retinal Pigment Epithelium
- •13.1.3.2 Müller Cells
- •13.1.3.3 Astrocytes
- •13.1.3.4 Pericytes
- •13.1.4 VEGF Receptors and VEGF Induced Signal Transduction
- •13.1.4.1 VEGF Receptors
- •VEGFR-1
- •VEGFR-2
- •Neuropilin
- •Heparan Sulfate Proteoglycan
- •13.2 Regulation of VEGF Expression
- •13.2.1 Transcriptional Regulation
- •13.2.2 Translational Regulation
- •13.2.3 Hypoxia Induced VEGF Regulation
- •13.2.4 Posttranslational Regulation
- •13.2.5 Autocrine VEGF Regulation
- •13.2.6 Pathological VEGF Production
- •13.2.6.1 Hyperglycemia
- •13.2.6.2 Oxidative Stress
- •13.2.6.3 Cytokines
- •13.2.6.4 Endoplasmic Reticulum
- •13.2.6.5 Additional Factors
- •13.3.1 Pegaptanib
- •13.3.2 Bevacizumab and Ranibizumab
- •13.3.4 siRNA
- •13.3.5 Small Molecule Tryrosine Kinase Inhibitors
- •13.3.6 Other Inhibitors
- •13.4.2 Interaction of VEGF Antagonists with Antiangiogenic VEGFxxxb
- •13.5 Conclusion
- •References
- •14.1 Introduction
- •14.2 NADPH Oxidase and Redox Signaling
- •14.3 Expression of NADPH Oxidase Subunit p22phox in the Retina
- •14.4 NADPH Oxidase and Choroidal Neovascularization
- •14.5 Implication and Therapeutic Potential of NADPH Oxidase in Development of CNV
- •14.6 Summary and Future Perspective
- •References
- •15.1 Introduction
- •15.2 Aging
- •15.3 Deposition and Formation of Oxidized LDL
- •15.6 Treatments for AMD
- •15.7 Conclusions
- •References
- •16.1 Introduction
- •16.2 HGF and Its Receptor (MET)
- •16.2.1 Production and Secretion of HGF
- •16.2.2 MET and Biological Effects of HGF
- •16.2.3 Signaling Pathways of HGF
- •16.2.4 HGF and MET in Disease States
- •16.4 HGF Protects RPE Cells from Oxidative Stress
- •16.4.1 HGF and RPE Cells
- •16.4.2 HGF Promotes Cell Survival
- •16.4.3 HGF Protects Cells from Oxidative Stress
- •16.4.4 HGF Protects RPE Cells from Hydrogen Peroxide
- •16.4.5 HGF Protects RPE Cells Against Ceramide Damage
- •16.4.6 HGF Protects RPE Cells from Glutathione Depletion
- •References
- •17.1 Introduction
- •17.2.1 Fundoscopy
- •17.2.2 Histology
- •17.2.3 Ultrastructure
- •17.3.1 Lipofuscin (A2E)
- •17.3.3 HtrA2/Omi
- •References
- •18.1 Introduction
- •18.2 Systemic Markers of Oxidative Stress
- •18.2.1 Redox Status
- •18.2.2 DNA Damage
- •18.2.4 Lipid Peroxidation
- •18.3 Defenses Against Oxidative Stress
- •18.3.1 Antioxidants
- •18.3.2 Antioxidant Enzymes
- •18.4 Oxidative Stress and Genetics
- •18.4.1 Antioxidant Enzyme Polymorphisms
- •18.5 Environmental Exposures and Oxidative Stress
- •18.5.1 Smoking
- •18.5.2 Light Exposure
- •18.6 AMD Treatments and Oxidative Stress
- •18.8 Summary and Conclusions
- •References
- •19.1 Characteristics of Cerium Oxide Nanoparticles
- •19.3 Mechanism of Nanoceria Uptake, Internalization, and Localization in the Cell
- •19.4 Biological Effect, Functional Mechanism, and Applications
- •19.4.1 Bacteria
- •19.4.2 Plants
- •19.4.3 Medical Usage
- •19.4.3.1 Radioprotectants
- •19.4.3.2 Burn Treatment
- •19.4.4 Medical Imaging
- •19.5 Stability of Nanoceria Under storage Conditions and Its Longevity in the Cell In Vivo
- •19.6 Oxidative Damage Results in Neurodegeneration
- •19.7.1 Prolong Cellular Life Span
- •19.7.2 Cardioprotection
- •19.8 Treatment of Ocular Disorders
- •19.8.1 Methodology
- •19.8.2 Prevention of Light Damage and Rescue of Retinal Function
- •19.8.3 Treatment of Degenerative Ocular Diseases
- •19.8.4 Treatment of Ocular Neovascular Diseases
- •19.9 Toxicity and Environmental Impacts
- •19.10 Conclusion and Future Directions
- •References
- •20.1 Introduction
- •20.2 Retinal Progenitor Cells (RPCs) Are Multipotential
- •20.4 Therapeutic Strategies for Repair and Regeneration of Retinal Cells: Repair of the RPE
- •20.5 Challenges for RPE Stem Cell Therapy
- •20.6 Characterization of RPE-Like Cells Derived from BMDCs
- •20.7 BMDCs Differentiate into Retinal Cells
- •20.8 Summary and Future of Cell Therapy for Dysfunctional RPE
- •References
- •21.1 Introduction
- •21.2 Carotenoids in Retinal Diseases
- •21.4 Polyphenols or Phenolic Esters in Retinopathies
- •21.4.1 Caffeic Acid Phenethyl Ester
- •21.4.2 Catechin
- •21.4.3 Curcumin
- •21.4.4 Proanthocyanidin
- •21.4.5 Resveratrol
- •21.5.2 Sulforaphane
- •21.6 Vitamins in Retinopathies
- •21.6.1 Vitamin A
- •21.7 Perspectives
- •References
- •22.1 Introduction
- •22.1.1 Neuroprotection as a Strategy for Retinal Degenerative Disease
- •22.2.2 Putative Mechanisms of CNS Neuroprotection
- •22.3.9 Conclusion
- •22.4 Mechanisms of Retinal Protection
- •22.4.1 Insights from In Vitro Models
- •22.5.1 Background to the Disease and the Associated Preclinical Data
- •22.5.2 Overview of the Clinical Development Program
- •References
- •23.1 Introduction
- •23.2 Pathogenesis
- •23.4 Pegaptanib
- •23.5 Bevacizumab
- •23.6 Ranibizumab
- •23.7.1 Ranibizumab
- •23.7.2 Bevacizumab
- •23.8 Comparison of AMD Treatment Trials (CATT)
- •23.9 Management of Nonresponders
- •23.11 Conclusion
- •References
- •24.1 Introduction
- •24.2 Rationale for Combination Therapy
- •24.3 Supporting Evidence for Combination Therapy
- •24.4 Currently Applied Combination Therapies
- •24.5 Challenges for Combination Therapy
- •References
- •25.1 Human Endothelial Progenitor Cells
- •25.3 Function of EPCs
- •25.3.1 EPCs in Vascular Repair and Neovascularization
- •25.4 EPCs in Diabetes
- •25.4.1 EPC as a Biomarker in Diabetes
- •25.4.1.1 EPC Dysfunction in Diabetes
- •25.4.1.2 Oxidative Stress and EPC Dysfunction in Diabetes
- •25.4.1.3 Therapeutic Angiogenesis by EPCs in Diabetic Retinopathy
- •25.5 Conclusion
- •References
- •26.1 Introduction
- •26.1.1 Nitric Oxide
- •26.1.2 Nitric Oxide Regulation
- •26.1.3 Nitric Oxide in Normal and Pathophysiological Conditions
- •26.2 Retinal Vascular Diseases: The Role of iNOS
- •26.2.1 Nitric Oxide in Diabetic Retinopathy
- •26.2.2 iNOS in Diabetic Retinopathy
- •26.2.2.2 iNOS and Leukocyte Adhesion to Retinal Vessels
- •26.2.2.3 iNOS and Retinal Cell Death
- •26.2.3 Proliferative Retinal Diseases
- •26.2.3.1 iNOS and Proliferative Retinal Diseases
- •26.2.3.2 iNOS and Ocular Neovascularization in Retinal Vascular Diseases
- •26.3 Conclusions
- •References
- •27.1 Introduction
- •27.2 Animal Model
- •27.2.1 LHP Preparation and Injection Procedure
- •27.2.2 Acridine Orange Digital Fluorography
- •27.3 Experimental Results
- •27.3.1 Leukocyte Rolling
- •27.3.2 Accumulated Leukocytes in the Retinal Microcirculation
- •27.3.3 Diameter of Major Retinal Vessels
- •27.3.4 SOD Treatment
- •27.4 Discussion
- •27.5 Conclusions
- •References
- •28.1 Introduction
- •28.1.2 Metabolism and Balance in Generation and Quenching of ROS
- •28.2 Role of Oxygen Concentration on Generation of ROS in the Developing Retina
- •28.3.1 Perinatal Considerations
- •28.3.2 Neonatal Considerations
- •28.3.2.1 Polyunsaturated Fatty Acids in Retina and Brain
- •28.3.2.2 Increased Oxidation
- •28.3.2.3 Reduced Antioxidant Enzyme Systems
- •28.3.3 Environmental Stimuli
- •28.3.3.1 Light
- •28.3.3.2 Oxygen Changes in Development and Prematurity
- •28.3.3.3 Nutrition
- •28.3.3.4 Effect of Blood Transfusions on Oxidative Stress in Prematurity
- •28.4 Evidence from Animal Models
- •28.4.1 Background
- •28.4.2 Effects of Hypoxia on Bioenergetic Oxygen Sensor Mechanisms and Related to ROP
- •28.4.2.2 NADPH Oxidase
- •28.4.2.3 Cytochrome p450 Monooxygenases (CYP)
- •28.4.2.4 eNOS
- •28.4.2.5 Heme Oxygenase
- •28.4.2.6 Metabolic Effects of Hypoxia
- •28.4.3 Laboratory Evidence of Antioxidants on Animal Models of ROP
- •28.5 Clinical Studies of Antioxidants on ROP
- •28.6 Genetics
- •28.7 Summary
- •References
- •29.1 Introduction
- •29.1.1 Oxidative Stress in Glaucoma
- •29.1.2 Oxidative Stress in Diabetic Retinopathy
- •29.1.3 Oxidative Stress in Age Related Macular Degeneration
- •29.1.4 Vascular Endothelial Growth Factor
- •29.1.5 VEGF Mediated Neuroprotection
- •29.1.6 Mechanisms of VEGF Protection Against Oxidative Stress
- •References
- •30.1 Introduction
- •30.1.1 Oxidation and Oxidative Stress
- •30.1.2 Reactive Oxygen Intermediates
- •30.1.3 ROIs and Cellular Retinal Damage
- •30.1.4 Light, Cellular Retinal Damage and AMD
- •30.1.5 Carotenoids
- •30.1.6 Chemistry of Carotenoids: Basic Structural Components
- •30.2 Building Blocks
- •30.3 The Polyene Backbone
- •30.5 Terminal Groups
- •30.5.1 Source of Macular Carotenoids
- •30.5.2 Macular Carotenoids: The Origins of Macular Pigment
- •30.5.3 The Functions of the Macular Carotenoids as Macular Pigment for AMD
- •30.6 Antioxidant Properties
- •30.6.1 The Functions of the Macular Carotenoids as Macular Pigment for Visual Performance
- •References
- •31.1 Introduction
- •31.2 Composition and Distribution
- •31.3 Selective Uptake and Deposition Process of MP
- •31.4 Measurements
- •31.4.1 Heterochromatic Flicker Photometry
- •31.4.4 Resonance Raman Spectroscopy
- •31.5 Antioxidant Mechanism of MP and Its Relation to Retinal Health and Disease
- •31.5.1 Oxidative Stress in Human Retina and the Antioxidant Mechanism of MP
- •31.5.2 MP in Human Eye Health and Disease
- •31.5.2.2 MacTel
- •31.5.2.3 Acuity
- •31.6 Ocular Carotenoid Supplementation Studies
- •31.7 Conclusion
- •References
- •Index
- •About the Authors
186 |
P.G. Sreekumar et al. |
viability [57Ð59]. Thus, strategies to restore mitochondrial GSH from depletion or to prevent the impairment of GSH mitochondrial transport may be of therapeutic signiÞcance in the treatment of several pathologies such as hypoxia and reperfusion injury, liver diseases, neurological disorders, diabetes, and aging [1].
9.2.3GSH as a ROS Scavenger
Among the cellular antioxidants, GSH reacts directly with ROS. It is a cofactor for the H2O2-removing enzyme glutathione peroxidase and for dehydroascorbate dehydrogenase, and it is thereby directly or indirectly involved in many ROS-detoxifying reactions [52]. Usually, generation of ROS oxidizes GSH to GSSG, ultimately reducing the total GSH level. However, studies have also shown that a reduction in the intracellular GSH is necessary for the formation of ROS [60]. GSH depletion has been shown to directly modulate both the loss of mitochondrial membrane potential and the activation of executioner caspases [52, 60]. GSH homeostasis plays a vital role in the maintenance of mitochondrial DNA and respiratory competency of cells [61]. In various types of untreated cultured mammalian cells, the levels of total GSH were found to be inversely correlated with the levels of DNA base modiÞcations [62]. Since mitochondria lack catalase, the metabolism of H2O2 is mainly accomplished by GSH, with the involvement of either GSH peroxidase or peroxiredoxin [1].
9.2.4GSH Distribution in the Retina and RPE in Health and Disease
The retina is one of the most vascularized tissues in the body and has one of the highest oxidative metabolic rates per tissue weight. The GSH system is one of the most important antioxidant systems involved in retinal protection. In early immunological studies of the rabbit retina, GSH was found to be mainly distributed in the Muller cells, horizontal cells, RPE, and the choroid [63]. The outer segments of the rod and cone photoreceptor cells were negative for GSH staining. Subsequent studies also supported these Þndings in Zebra Þsh, monkey, and guinea pig [64Ð67]. However, Winkler postulated that the deÞciency of GSH will not damage the outer segments under unstressed conditions because periodic renewal of outer segments replaces products of oxidation damage before they increase to the toxic level [68]. Under pathological situations, this process alone is not capable of protecting photoreceptors, and accordingly, photoreceptors are believed to be highly vulnerable to cell death or degeneration [68]. Oxidative stress caused by exposure of RPE cells to cigarette smoke extract sensitizes cells to apoptosis by altering mitochondrial functions and decreasing intracellular GSH [69]. GSH depletion by systemic injection
9 Glutathione Metabolism and Its Contribution to Antiapoptotic PropertiesÉ |
187 |
of L-buthionine sulfoximine caused unregulated oxidative cell stress and increased cell death in the retina [70]. The cells in the inner nuclear layer are affected earlier than the cells in other layers of the retina [70]. There is abnormal regulation of several mitochondrial proteins, including ATP synthase, cytochrome C oxidase complex, and mitochondrial HSP70 in the AMD retina [71]. A link between mitochondrial dysfunction and RPE degeneration has been reported by several laboratories, including ours [11, 27, 72, 73]. Recently, He and Tombran-Tink have provided evidence that increased accumulation of defective mitochondria in RPE cells with aging contributes to reduced function of these cells and increased pathological consequences in the retina [74].
9.3a-Crystallins: Expression, Function, and Tissue Distribution
The vertebrate crystallins are divided into three families: a-, b-, and g-crystallins [75, 76]. a-Crystallin, a predominant protein of vertebrate eye lens, constitutes up to 50% of the total water-soluble fraction. In their native form, the a-crystallin protein complexes are the largest among the crystallins and are normally isolated as a large heteropolymer [77]. Genes encoding for aA and aB-crystallins are localized on chromosome 21 and 11, respectively [78, 79]. a-Crystallins share a homologous C-terminal domain of ~80 amino acid residues with the family of the ubiquitous sHsp [80], whereas the N-terminal part differs in sequence and length, leading to molecular masses of 16Ð42 kDa for sHsps in different organisms [79]. The main feature of the native a-crystallin complex is its chaperone function, which is ATP-independent [78].
For many years, it was believed that the expression of a-crystallin is restricted to the ocular lens. However, in the last decade, the presence of aB-crystallin is shown in other ocular tissues, such as cornea, optic nerve, retinal glia, astrocytes, and Muller cells, and in nonocular tissues, such as cardiac, skeletal muscle, skin, kidney, brain, and lungs [81, 82]. In contrast to aB-crystallin, aA-crystallin is believed to be largely lens-speciÞc; however, low levels of aA-crystallin have been localized in spleen, thymus, and retina [83Ð86]. Analysis of the expression of crystallins in the mouse retina showed that aA- and aB-crystallins were found in the inner and outer nuclear layers and the RPE layer [86].
9.3.1a-Crystallins in Ocular Pathology
Dysregulation of aB-crystallin expression occurs in multitude of pathologies, especially in degenerative diseases of central nervous system and retina such as Parkinson disease, multiple sclerosis, CreutzfeldtÐJakob disease, Alzheimer disease,
188 |
P.G. Sreekumar et al. |
|
Table 9.1 Glutathione and a-crystallins in disease |
|
|
|
|
|
Disease |
Tissue or cellular GSH |
References |
|
|
|
Diseases involving increase (↑) or decrease (↓) GSH |
|
|
Alzheimer disease |
Brain; red blood cells, blood serum ↓ |
[134Ð136] |
Parkinson disease |
Substantia innominata, cingulate cortex, |
[136Ð138] |
|
blood serum, blood plasma, |
|
|
substantia nigra ↓ |
|
Hearing loss |
Cochlea ↓ |
[139] |
Cancer |
B16M cells; liver ↑ |
[140, 141] |
Myocardial infraction |
Cardiomyocytes ↓ |
[142Ð144] |
Chronic obstructive |
Lung epithelial cells, lung tissue, |
[145, 146] |
pulmonary diseases |
bronchial epithelial cells ↓ |
|
Cystic Þbrosis |
Blood serum ↓ |
[147] |
Rheumatoid arthritis |
Blood serum, erythrocytes ↓ |
[148, 149] |
CrohnÕs disease |
Plasma, intestinal mucosa, neutrophils ↓ |
[150, 151] |
Multiple sclerosis |
Blood, brain and spinal cord samples; |
[152, 153] |
|
fronto-parietal regions of the brain ↓ |
|
Psoriasis |
Erythrocytes, blood plasma ↓ |
[154] |
AIDS |
Blood samples ↓ |
[155] |
Insulin-dependent |
Blood serum ↓ |
[156] |
diabetes mellitus |
|
|
Ocular disorders |
|
|
Age-related nuclear cataract |
Lens, lens cortex and epithelium ↓ |
[4, 5] |
Glaucoma |
Retina, retinal ganglion cells ↓ |
[3, 157] |
Age-related macular |
Blood plasma ↓ |
[158, 159] |
degeneration |
|
|
|
|
|
Disease |
Change in Tissue a-crystallin/mutant |
References |
|
|
|
Diseases involving a-crystallins |
|
|
Alexander disease |
Brain (aB-crystallin) ↑ |
[160] |
CreutzfeldtÐJakob disease |
Brain (aB-crystallin) ↑ |
[161, 162] |
Alzheimer disease |
Brain (aB-crystallin) ↑ |
[163] |
Parkinson disease |
Brain (aB-crystallin) ↑ |
[164] |
Desmin-related myopathy |
R120G mutation (aB-crystallin) |
[165] |
Multiple sclerosis |
Brain (aB-crystallin) ↑ |
[16, 166] |
Ocular disorders |
|
|
Age-related macular |
Retina (aA and aB-crystallin) ↑ |
[92] |
degeneration |
|
|
Autoimmune uveitis |
Retina (aA crystallin) ↑ |
[167] |
Retinoblastoma |
Retina (aA crystallin) ↑ |
[168] |
Retinal degeneration |
Retina (aB crystallin) ↑ |
[169] |
Cataract |
Mutation (aA and aB-crystallin) |
[97, 170, |
|
|
171] |
|
|
|
amyotrophic lateral sclerosis, Alexander disease, and AMD [87] (see Table 9.1). Studies by Brady et al. highlighted the importance of aB-crystallin, not only in the lens but also in affecting muscle integrity[88]. In various tissues, aB-crystallin is associated with different cytoskeletal elements, such as tubulin, actin, and desmin
9 Glutathione Metabolism and Its Contribution to Antiapoptotic PropertiesÉ |
189 |
[89, 90]. It is believed that aB-crystallin is involved in cell growth and differentiation and that it also helps in Golgi reorganization during cell division [78, 91]. BruchÕs membrane, drusen and the subjacent choroidal connective tissue from AMD tissues showed greater immunoreactivity for aA- and aB-crystallins, suggesting that it may represent a stress response to protect RPE in AMD [92]. Recent quantitative proteomic analysis of the macular BruchÕs membrane/choroid complex provides strong evidence of the upregulation of a-crystallins in AMD samples [93]. Interestingly, aB-crystallin is also found in extracellular drusen deposits and has been reported as a component of the interphotoreceptor matrix, suggesting the possibility that it may be secreted [94, 95].
The major disorder caused by mutations in the aA-crystallin gene is cataract (of different forms), sometimes associated with microcornea or microphthalmia. Besides the loss in chaperone activity, the pathology may arise from the altered interaction with the lens cytoskeleton proteins such as actin, tubulin, or intermediate Þlaments [78, 96]. The Þrst dominant cataract mutation affecting the human aA- crystallin gene described is the Arg116Cys mutation [97]. Subsequently, several other independent studies also reported mutation in the same position, suggesting this position as a mutational hotspot in the aA-crystallin gene. Among the two mechanisms proposed to explain enhanced protein aggregation due to a-crystallin mutations, the Þrst suggests an alteration in the structure of the chaperone protein and the second a loss of regulation of the oligomeric structure of a-crystallin, resulting in higher coaggregation of mutant protein and substrates [98]. Since the Arg116Cys mutation was the Þrst human aA-crystallin mutation reported, a broad variety of experimental approaches have been undertaken to Þnd out the functional consequences of this mutation. The mutant protein shows reduced chaperone activity [99] and interaction with actin [100]. In addition to the nine aA-crystallin mutations in human, there are also four aA-crystallin mutants reported in mouse. Although aA-crystallin is expressed outside the lens, only cataracts are reported to be caused by mutations in the aA-crystallin encoding gene [101].
In contrast to the clear relationship of aA-crystallin mutations and the formation of cataracts, the role of aB-crystallin is more heterogeneous. In humans, nine mutations are reported affecting the aB-crystallin gene [101]. A few of them are associated with dominant cataracts only, but some are also suggested to be causative for desmin-related myopathy or dilated cardiomyopathy [96]. The missense mutation p.Gly154Ser in aB-crystallin gene is associated with a late-onset distal vacuolar myopathy with protein aggregates [102]. The R120G mutation in aB-crystallin (CryABR120G) causes desmin-related myopathy characterized by early mitochondrial dysfunction and activation of intrinsic (mitochondrial-based) apoptotic signaling [103]. The missense mutation p.Gly154Ser in exon 3 of Cryab gene, previously described in isolated cardiomyopathy [104], is also causative for late-onset progressive distal myopathy without cardiac involvement and without signiÞcant cataracts [102]. A mutation at nucleotide 32 in the Þrst exon of aB-crystallin resulting in an amino acid change from arginine to histidine at codon 11 (R11H) was responsible for the autosomal dominant nuclear congenital cataract [105]. However, when compared with aA-crystallin gene mutations, mutations in aB-crystallin genes caused more
190 |
P.G. Sreekumar et al. |
serious cardiac problems than retinal disorders. Posttranslational modiÞcations of aA- and aB-crystallin, including truncation, deamidation, oxidation, glycation, phosphorylation, and racemization/isomerization, promote cataract formation in aging organisms through modiÞcation of chaperone activity and solubility [12].
Generation of mice lacking aA- and aB-crystallin has provided valuable insights into the functional roles of these proteins in the lens. Targeted disruption of aA-crystallin gene in mice induces cataract and dense cytoplasmic inclusion bodies in lens Þber cells [106]. The presence of dense aB-crystallin inclusion bodies was also observed in the central lens Þber cells of aA-crystallin knockout (aA−/−) mice, suggesting the possible role of aA-crystallin for maintaining the solubility of other crystallins in the lens [106]. It was also found that the absence of aA-crystallin increases cell death during the mitotic phase. On the other hand, disruption of aB-crystallin gene (HSPB2, an adjacent gene which was also deleted) did not produce cataracts or abnormal retinal phenotype, but aB-crystallin knockout (aB−/−) mice showed skeletal muscle degeneration, spine curvature, and a life span one half that of wild type mice [88]. Further, lens cells from aB−/− mice exhibited a greater tendency for hyper-proliferation and genomic instability [78]. Combined deletion of aA- and aB-crystallin genes leads to gross abnormalities of the Þber cell structure, consistent with their important role in lens Þber development [107]. aA−/−/aB−/−-crystallin double knockout mouse lenses are signiÞcantly smaller than wild-type, and Þber cell formation is severely disturbed [107] due to caspase-dependent Þber cell degeneration [108].
An intriguing property of aB-crystallin is its ability to undergo phosphorylation at multiple sites and therefore it is subject to modiÞcation by several transduction pathways. aB-crystallin has serine phosphorylated sites in the N-terminal part of the polypeptide, and close to the a-crystallin domain [109]. aB-crystallin is phosphorylated at three serine sites corresponding to residues 19, 45, and 59. At least two pathways are implicated in the aB-crystallin phosphorylation: the mitogenactivated protein kinases associated protein kinases 2 are responsible of the phosphorylation of serine 59, while p42/p44 MAP Kinase appears to control serine 45. The kinase responsible of the phosphorylation of serine 19 is still not known [109]. Multiple phosphorylation sites of aA-crystallin have been reported in the literature although all the phosphorylation sites have not been characterized and pathways of activation not studied [110, 111].
9.3.2Nonchaperone Functions of a -Crystallins
As stated earlier, a-crystallins are multifunctional proteins involved in many cellular processes including those which are not directly related to protein folding and aggregation [96]. Some of these functions include maintaining eye lens transparency [106]; thermotolerance [112]; resistance to apoptosis [11, 106, 113, 114]; cytoskeleton modulation [115]; prevention of amyloid formation [116]; various developmental processes [117]; protection against oxidative stress [11, 118, 119]; and neuroprotection [16, 118]. The interaction between aB-crystallin and a
9 Glutathione Metabolism and Its Contribution to Antiapoptotic PropertiesÉ |
191 |
proteosomal subunit might suggest that a-crystallins facilitate not only refolding but also selective degradation of target proteins [109]. Our laboratory has recently shown that aB-crystallin plays an important role in the regulation of vascular permeability and angiogenesis by modulating vascular endothelial growth factor in laser-induced choroidal neovascularization and in retinopathy of prematurity models [120, 121].
9.3.3Secretory Function of a B-Crystallin in RPE and Its Relevance
Until recently, it was thought that a-crystallins are intracellular proteins since they lack secretory signal sequence. We have shown in human RPE cells and in polarized human RPE monolayers that aB-crystallin is secreted by a nonclassical pathway involving exosomes [118]. In highly polarized RPE monolayers, aB-crystallin was selectively secreted toward the apical, photoreceptor-facing side under steady-state conditions. Severe oxidative stress resulted in barrier breakdown and release of aB- crystallin to the basolateral choroidal side. To support these Þndings in vivo in mouse retinal sections, we localized aB-crystallin in the interphotoreceptor matrix. Under oxidative stress, the secreted aB-crystallin is taken up to offer protection from apoptosis by inhibition of caspase 3 and PARP activation [118]. Further, we also found that aB-crystallin was taken up by photoreceptors in mouse retinal explants exposed to oxidative stress. These results demonstrate an important role for aB-crystallin in maintaining and facilitating a neuroprotective outer retinal environment and may also explain the accumulation of aB-crystallin in extracellular subRPE deposits in the stressed microenvironment in AMD.
9.4Interlink Between GSH and a -Crystallins
Several reports have shown that GSH is the coenzyme of various redox reactions [20]. The antioxidant activity of a-crystallin was found to depend on reduced GSH [122]. Incubation of a-crystallin with oxidized GSH results in signiÞcant loss of its chaperone activity because of the formation of proteinÐGSH mixed disulÞdes [123]. An in vitro study on the effect of oxidized and reduced GSH on the chaperone activity of a-crystallin demonstrated that reduced GSH enhanced the chaperone function while oxidized GSH diminished the activity, suggesting that GSH may modulate the target protein which could inßuence the chaperone activity of a-crystallin [124]. We have shown that overexpression of a-crystallins offers protection, while deÞciency of a-crystallins renders RPE cells susceptible to oxidative stress-induced apoptosis [11, 13]. A direct positive correlation between aA-crystallin and GSH was found in lens epithelial cells overexpressing aA-crystallin, whereas absence of
